1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Lilly(Eli) & Co

Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. It was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today it remains true to that mission in all its work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
David Ricks

Lilly Corporate Ctr
Indianapolis, Indiana 46285-0001
Phone: 13172762000


Which Companies Will Join the Trillion-Dollar Team in 2024? Our 3 Best Guesses
Apr 24, 2024 18:51pm

The majority of leading global indices reached new highs in 2024, fueled by loose financial conditions and burgeoning enthusiasm for artificial intelligence ( AI ). In the U.S., this rally pushed the S&P 500 to fresh highs. And unwavering investor optimism and the prospect of stocks joining the trillion-dollar club maintained the surge. Historically, the markets prefer challenging complacency among investors. This lesson seems particularly important today. Initially, market sentiment was buoyed by expectations of multiple interest rate cuts by the Federal Reserve, with predictions of up to seven reductions by January 2025. However, contrary to these expectations, recent data indicates stronger-than-anticipated economic growth and rising inflation. Yet, investors remain undeterred. They are pivoting to a narrative of a reaccelerating economy bolstering the markets. Despite this optimism, there are signs of caution. Analysts have been revising earnings estimates downward for this year and next, while the stock market’s strength is concentrated in a select group of mega-cap stocks.

Meet Eli Lilly''s Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
Apr 24, 2024 10:40am

Lilly recently announced news that could solve a big problem.

Source:The Motley Fool
REITs Q1 Earnings Begin On Solid Note
Apr 23, 2024 16:31pm

Given the recent talk about higher interest rates being a headwind for real estate investment trusts (REITs), investors might anticipate that first-quarter operating results could be lackluster or subpar. However, many initial REIT earnings reports are much better than expected, with several REITs beating the analyst estimates on funds from operations (FFO) or adjusted funds from operations (AFFO). Occupancy levels are still high and full-year 2024 FFO guidance looks sound. Take a look at three REITs that just declared earnings and are showing up the analyst consensus estimates. Alexandria Real Estate Equities Inc. (NYSE: ARE ) is a Pasadena, California-based REIT with a portfolio of 800 tenants devoted to life science, agtech and advanced technology companies in what its website calls "top innovation clusters." These areas include cities like Boston, New York City, Seattle and San Francisco. Mega campuses make up 75% of its annual rental revenue. Alexandria is a member of the S&P 500.

3 Stocks With the Potential to Surpass Analyst Expectations for 2024
Apr 23, 2024 11:00am

Many investors look to analysts’ expectations to guide their movements each quarter. Typically, those investors can reasonably use estimates as a reference. However, some stocks rise above and beyond those expectations with breakthrough products, exciting partnerships/deals and incredible quarterly performances. Stocks with such potential give investors a golden opportunity to buy at a lower price but enjoy considerable returns after a company’s performance blows away any and all estimates. We have gathered the three stocks to buy, destined for tremendous growth and most likely to beat analyst expectations this year. Let’s learn more about each company’s exciting products set to be released this year, propelling these stocks’ 2024 performances to skyrocket. Viking Therapeutics (VKTX) Source: ra2 studio/Shutterstock Viking Therapeutics (NASDAQ: VKTX ) is capitalizing on one of the hottest trends right now to propel its stock higher. The company’s new obesity drug, VK2735, has made great strides, passing clinical trials and getting closer and closer to approval and release.

Eli Lilly buys new injectable medicine manufacturing facility from Nexus Pharma
Apr 23, 2024 08:15am

Indianapolis: Eli Lilly and Company and Nexus Pharmaceuticals , LLC have … sterile manufacturer in the pharmaceutical industry. The acquisition … manufacture specialty and generic drugs that are easier … : CDSCO Panel Approves Eli Lilly ''s protocol amendment …

Source:EIN News Pharmaceuticals
Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma
Apr 22, 2024 18:21pm

On Monday, Eli Lilly and Company (NYSE: LLY ) agreed to acquire a manufacturing facility from Nexus Pharmaceuticals. The deal terms were not disclosed. The acquisition of this FDA-approved facility in Pleasant Prairie, Wisconsin, will further expand Lilly’s global parenteral (injectable) product manufacturing network and support increased demand for the company’s medicines. Related: Novo Nordisk/Eli Lilly’s Weight Loss Drugs Does Not Cause Suicidal Behaviors – After FDA, European Medicines Agency Says . Lilly estimates that production at this facility could begin at the end of 2025. The Pleasant Prairie facility does not provide contract manufacturing services, allowing the facility to be solely dedicated to Lilly’s manufacturing. Eli Lilly is grappling with a … Full story available on Benzinga.com

Eli Lilly (NYSE:LLY) Notches Up on New Manufacturing Plans
Apr 22, 2024 17:04pm

For pharmaceutical company Eli Lilly (NYSE:LLY), it’s been doing some great things of late with a string of drugs. And, seeing that supply is getti…

Eli Lilly acquires new injectable medicine manufacturing plant
Apr 22, 2024 16:09pm

Eli Lilly (NYSE:LLY) announced today that it agreed to acquire a manufacturing facility from sterile manufacturer Nexus. Buying the FDA-approved facility in Pleasant Prairie, Wisconsin, further expands Lilly’s global parenteral (injectable) manufacturing network. It also supports increased demand for the company’s medicines, Lilly said in a news release. The company expects that production at the […] The post Eli Lilly acquires new injectable medicine manufacturing plant appeared first on Drug Delivery Business .

Source:Drug Delivery Business
Eli Lilly to acquire manufacturing facility from Nexus Pharma
Apr 22, 2024 16:04pm

… that it will acquire a manufacturing facility from Nexus Pharmaceuticals to … had signaled that investments in manufacturing and supply capacity would progressively …

Source:EIN News Manufacturing
Eli Lilly And The Alzheimer''s Dilemma (Rating Upgrade)
Apr 22, 2024 04:58am

Approval of donanemab could have a modestly positive impact on Eli Lilly. Click here to see why LLY stock is a Hold.

Source:Seeking Alpha